We investigate the Asperger Syndrome, it's a pervasive developmental condition related to autism. It manifests in highly individual ways and can have both positive and negative effects on a person. It is recognized by the medical community as one of five neurobiological pervasive developmental disorders (PDD) considered to be part of the autistic spectrum. It is typically characterized by issues with social and communication skills.
Conditions
Interventions
Product Name: Syntocinon spray
Product Code: Syntocinon spray
Pharmaceutical Form: Nasal spray*
Pharmaceutical form of the placebo: Nasal spray*
Route of administration of the placebo: Nasal use
Sponsors
CNRS: VAN DER REST Michel
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: *Signature of the approval by the patient or by the person who represents the parental authority for minors. *The diagnosis of Asperger syndrome *The age of subjects (women or men) between 16 and 45 years old *To be affiliate to the social security Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: *Presence of previous symptom of schizophrenia *Presence of neurological desease *Presence of epileptic crisis *Presence of pregnancy, or breast-feeding women *Taking anesthetics or medicamentation *To be in the exclusion periode of another study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: This project aims to study the possibility of having an enhancement in the social life of Asperger patients. We will study the effect of syntocinon spray on major fields wich caractarize the bases of any social interaction: the contact of the eyes, the recognition of emotion, the understanding of the intentions of the others and the confidence in others. ;Secondary Objective: We will deduce the difficulties of the patients with Asperger syndrome in identifing the face, in recognizing the emotion from a face, in detecting the eye gaze and in interacting with another person in a trust game. This deduction will be accomplished with a comparison with a control groupe.;Primary end point(s): | — |
Countries
France
Outcome results
None listed